Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …

BACKGROUND: Phase 1-2 trials involving patients with resectable, macroscopic stage III
melanoma have shown that neoadjuvant immunotherapy is more efficacious than adjuvant …

Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …

Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …

Neoadjuvant ipilimumab and nivolumab induces high pathologic response rates (pRRs) in
clinical stage III nodal melanoma, and pathologic response is strongly associated with …

Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …

The gut microbiota shapes the response to immune checkpoint inhibitors (ICIs) in cancer,
however dietary and geographic influences have not been well-studied in prospective trials …

Cancer vaccines aim to direct the immune system to eradicate cancer cells. Here we review
the essential immunologic concepts underpinning natural immunity and highlight the …

The progression of cancer involves a critical step in which malignant cells escape from
control by the immune system. Antineoplastic agents are particularly efficient when they …